论文部分内容阅读
目的探讨核苷酸切除修复交叉互补基因(ERCC1)和人表皮生长因子(C-erbB2)在子宫内膜癌组织中的表达及其对化疗联合舒肝益肾方疗效的影响。方法将51例子宫内膜癌患者作为子宫内膜癌组,20例子宫内膜正常者为对照组。子宫内膜癌组给予化疗联合中药疏肝益肾方治疗。检测2组子宫内膜组织中ERCC1及C-erbB2表达,分析子宫内膜癌患者组织中C-erbB2、ERCC1表达对中西医结合治疗子宫内膜癌疗效的影响。结果 C-erbB2、ERCC1在子宫内膜癌组织中阳性表达随组织学分级增加而增强,G3级C-erbB2阳性率明显高于G1级和G2级(P<0.05);G3级的ERCC1阳性率明显高于G1级(P<0.05)。C-erbB2、ERCC1在子宫内膜癌组中阳性表达率明显高于对照组(P<0.05或P<0.01)。子宫内膜癌组C-erbB2、ERCC1阳性表达者的中西医结合疗效明显低于C-erbB2、ERCC1阴性表达者(P<0.05)。结论 ERCC1和C-erbB2表达状态有利于判断子宫内膜癌病理分级,并可用于疗效评估。
Objective To investigate the expression of ERCC1 and C-erbB2 in endometrial carcinoma and its effect on the therapeutic effect of chemotherapy combined with Shugan Yishenfang. Methods 51 cases of endometrial cancer as endometrial cancer group, 20 cases of endometrial normal control group. Endometrial cancer group given chemotherapy combined with Chinese medicine Shugan Yishen Fang treatment. To detect the expression of ERCC1 and C-erbB2 in endometrial tissues of two groups, and to analyze the effect of C-erbB2 and ERCC1 expression in the treatment of endometrial carcinoma treated with traditional Chinese and western medicine. Results The positive expression of C-erbB2 and ERCC1 in endometrial carcinoma increased with histological grade, and the positive rate of G-level C-erbB2 was significantly higher than that of G1 and G2 (P <0.05). The positive rate of G-stage ERCC1 Significantly higher than the G1 level (P <0.05). The positive rate of C-erbB2 and ERCC1 in endometrial carcinoma was significantly higher than that in the control group (P <0.05 or P <0.01). The efficacy of TCM and WM combined with C-erbB2 and ERCC1 positive expression in endometrial carcinoma was significantly lower than that in C-erbB2 and ERCC1-negative (P <0.05). Conclusion The expressions of ERCC1 and C-erbB2 are helpful to judge the pathological grade of endometrial carcinoma and can be used for evaluation of curative effect.